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In the present study we characterize the properties of the
potent MCT1 (monocarboxylate transporter 1) inhibitor AR-
C155858. Inhibitor titrations of L-lactate transport by MCT1 in
rat erythrocytes were used to determine the Ki value and number
of AR-C155858-binding sites (Et) on MCT1 and the turnover
numberofthetransporter(kcat).Derivedvalueswere2.3+ −1.4 nM,
1.29+ −0.09 nmol per ml of packed cells and 12.2+ −1.1 s
−1
respectively. When expressed in Xenopus laevis oocytes, MCT1
and MCT2 were potently inhibited by AR-C155858, whereas
MCT4 was not. Inhibition of MCT1 was shown to be time-
dependent,andthecompoundwasalsoactivewhenmicroinjected,
suggesting that AR-C155858 probably enters the cell before
binding to an intracellular site on MCT1. Measurement of the
inhibitor sensitivity of several chimaeric transporters combining
different domains of MCT1 and MCT4 revealed that the binding
site for AR-C155858 is contained within the C-terminal half of
MCT1, and involves TM (transmembrane) domains 7–10. This
is consistent with previous data identifying Phe
360 (in TM10) and
Asp
302 plus Arg
306 (TM8) as key residues in substrate binding
and translocation by MCT1. Measurement of the Km values of the
chimaeras for L-lactate and pyruvate demonstrate that both
the C- and N-terminal halves of the molecule inﬂuence transport
kinetics consistent with our proposed molecular model of MCT1
and its translocation mechanism that requires Lys
38 in TM1 in
addition to Asp
302 and Arg
306 in TM8 [Wilson, Meredith, Bunnun,
SessionsandHalestrap(2009)J.Biol.Chem.284,20011–20021].
Key words: chimaeric transporter, erythrocyte, lactate transport,
monocarboxylate transporter (MCT), Xenopus oocytes.
INTRODUCTION
Thereare14membersoftheMCT(monocarboxylatetransporter)
family (SLC16) encoded by the human and mouse genomes
[1]. Of these only MCT1, MCT2, MCT3 and MCT4 have
been demonstrated to catalyse the bidirectional proton-linked
transport of short-chain monocarboxylates such as L-lactate and
pyruvate across the plasma membrane of mammalian cells [2–
6]. MCT1 is expressed in most tissues and facilitates lactic acid
uptake for oxidation in heart and red skeletal muscle, and for
gluconeogenesis in the liver and kidney of some species [7–
11]. MCT1 is also used for lactic acid efﬂux by some cells that
are exclusively glycolytic, such as erythrocytes, and by all cells
under hypoxic conditions [1,10,12]. MCT2 is a higher-afﬁnity
transporter [3] whose expression is more restricted and highly
species-dependent [1]. In some species it is the dominant MCT
isoform in the kidney and liver where it facilitates lactic acid
uptakeforgluconeogenesis[9,13].Itisalsoexpressedinneurons,
especially at the post-synaptic density, and has been proposed to
provide the uptake pathway for the oxidation of lactate produced
by the more glycolytic astrocytes [14,15]. MCT3 expression is
conﬁned to the basal membrane of the retinal pigment epithelium
and choroid plexus epithelia [16,17], but detailed information
on its substrate and inhibitor speciﬁcity is lacking [4]. MCT4 is
a lower-afﬁnity transporter [5,6] and is primarily expressed in
highly glycolytic cells, such as white muscle ﬁbres, where it is
used to facilitate lactic acid efﬂux from the tissue [18,19]. Most
cells can up-regulate MCT4 expression under hypoxic conditions
when glycolytic ﬂux is enhanced and this is mediated through
transcriptional control by HIF-1α (hypoxia-inducible factor 1α)
[20].
In view of the importance of plasma membrane lactic acid
transport in metabolism, it would be desirable to have a speciﬁc
inhibitor of each isoform that could probe their individual
metabolic roles. A range of inhibitors of MCTs have been
described, including the α-cyanocinnamate derivatives, stilbene
disulfonates such as DIDS (di-isothiocyanostilbene disulfonate),
phloretin, bioﬂavenoids such as quercetin and organomercurial
reagents such as p-chlomercuribenzene sulfonate (see [1,21,22]).
However, none of these is speciﬁc for inhibition of
MCTs and thus they cannot be used with conﬁdence in
metabolic studies. This reservation applies particularly to
α-cyano-4-hydroxycinnamate that some workers have used on
the assumption that it is a speciﬁc MCT inhibitor (for example
see [23–25]). However, this agent is at least two orders of
magnitude more potent at inhibiting the mitochondrial pyruvate
carrierthanMCT1[26–29].Previously,anewclassofspeciﬁcand
extremely high-afﬁnity inhibitors of MCT1 have been discovered
by AstraZeneca [30–32]. These compounds were originally
identiﬁed as potent inhibitors of T-lymphocyte proliferation that
act as immunosuppressants and were subsequently shown to bind
to MCT1 and MCT2, but not MCT4 [30]. Since T-lymphocyte
activation and proliferation is accompanied by a large (up to 14-
fold) stimulation of glycolysis, it would appear that inhibiting
MCT1 and so preventing the efﬂux of the resulting lactic acid is
responsibleforthecompounds’immunosuppressiveactivity[30].
Abbreviations used: BCECF, 2 -7 -bis(carboxyethyl)-5(6)-carboxyﬂuorescein; DIDS, di-isothiocyanostilbene disulfonate; MCT, monocarboxylate
transporter; TM, transmembrane.
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Figure 1 Inhibition of L-lactate uptake into rat erythrocytes by AR-C155858
Raterythrocyteswerefreshlyisolatedandresuspendedatthespeciﬁedhaematocritasoutlinedin
the Experimental section. Cells were pre-incubated for 1 h at room temperature in the presence
or absence of the speciﬁed concentration of AR-C155858 (structure shown). Transport was
measured by continuous monitoring of the extracellular pH, and calibration of pH changes in
termsofprotonuptakewasachievedbyadditionofstandardizedNaOH(10μMﬁnal)justbefore
addition of 10mM L-lactate to initiate transport. Initial rates of transport were calculated by
ﬁrst-order regression analysis of the time course of pH change. The data were then ﬁtted by
non-linear least squares inhibition to the equation for a tight-binding non-competitive inhibitor
usinginhibitorconcentrationandhaematocritasthetwox-variables[41,42].Thederivedvalues
(+ −S.E. of the ﬁt shown) for the Ki and concentration of binding sites were 2.3+ −1.4 nM and
1.29+ −0.09 nmol per ml of packed cells respectively.
In the present study we seek to characterize the mode of
action of one of these potent MCT1 inhibitors, AR-C155858. We
have studied the concentration dependency of AR-C155858
inhibition of lactate transport into rat erythrocytes mediated by
endogenous MCT1, as well as its effects on the activity of MCT1,
M C T 2a n dM C T 4e x p r e s s e di nXenopus laevis oocytes. We show
thatAR-C155858inhibitsMCT1andMCT2withsimilarpotency,
but is inactive against MCT4, and that inhibition is exerted by the
drug binding to a site on MCT1 accessible from the cytosol.
The use of MCT1/MCT4 chimaeric transporters reveals that this
bindingsiteiscontainedwithinTM(transmembrane)helices7–10
of MCT1. In rat erythrocytes a detailed analysis of the inhibition
of lactate transport by AR-C155858 has enabled us to determine
the turnover number (kcat) of MCT1 (12.2 s
−1 at 6◦C) and the Ki
value for AR-C155858 (2.3 nM).
EXPERIMENTAL
Materials
X. laevis toads were obtained from Xenopus Express and
oocytes were harvested as described previously [33]. All
reagents were obtained from Sigma unless otherwise stated.
Polyclonal antibodies against the C-terminal 16 amino acids
of rat MCT1, MCT2 and MCT4, and against a 17 amino acid
sequence between TM7 and TM8 of MCT1 were raised in
rabbits as described previously [9,18,34]. Anti-rabbit secondary
antibodies for immunoﬂuorescence microsocopy were from
Jackson ImmunoResearch. L-[
14C]Lactate was obtained from
GE Healthcare and [
14C]pyruvate was from PerkinElmer. AR-
C155858 (whose structure is shown as an inset to Figure 1) was
obtained from AstraZeneca and made up as a 10 mM stock in
DMSO.
Methods
Generation of MCT chimaeras of rat MCT1 and MCT4 was
performed by PCR using pfu Taq polymerase (Roche). The
two appropriate segments of MCT1 and MCT4 were produced
with a region of overlapping sequence that was used to splice
the two together to produce the desired chimaera. For the
MCT1/4 and MCT4/1 chimaeras the switch occurs at the end
of the loop between TMs 6 and 7 which contains the conserved
sequence LDLS. For the MCT1/4TM11 and MCT4/1TM11
chimaera the switch occurs at the beginning of TM11 containing
the conserved sequence FSSA. However, for the C-terminal
chimaeras MCT1/4c and MCT4/1c, where the switch occurs at
the beginning of the C-terminus, there is no conserved sequence
and thus a region of complimentarity was manufactured using
modiﬁed primers [35]. A C-terminal truncation of MCT1 was
produced using PCR to amplify the MCT1 sequence minus the
C-terminus, and this was subsequently inserted into the oocyte
expression vector pGHJ with the addition of a stop codon
in the vector downstream of the MCT sequence. Sequences
for all primers used are given in Supplementary Table S1 (at
http://www.BiochemJ.org/bj/425/bj4250523add.htm) and were
designedtobebetween15and30basesinlength.Typically,foran
MCTfragment,thermocyclingwasperformedusingthefollowing
parameters: 30 s at 95◦C, 30 s at 55◦C and a 1.5 min extension
at 72◦C for 30 cycles. Subsequently, appropriate fragments of
MCT1 and MCT4 with complimentary sequence in the cross-
over region were combined using PCR with primers to the
5
 -a n d3
 -UTR (untranslated region) of MCT1 and MCT4. Here,
thermocycling was performed using the following parameters:
30 s at 95◦C, 30 s at 55◦C and a 1 min extension at 72◦C
for 10 cycles followed by 30 s at 95◦C, 30 s at 50◦Ca n da
1 min extension at 72◦C for 25 cycles. The MCT chimaeras
were subsequently ligated into the pGHJ oocyte expression
vector. For the MCT1/4 and MCT4/1 C-terminal chimaeras, the
C-terminal regions were brought into the correct reading frame
by a single base deletion and addition respectively using site-
directed mutagenesis with the QuikChange® kit (Stratagene) as
described previously [36]. Conﬁrmation that chimaera constructs
had been correctly engineered was provided by sequencing (The
Sequencing Service, University of Dundee, Dundee, U.K.).
Measurement of MCT1 activity in rat erythrocytes
L-Lactate transport into rat erythrocytes was measured by
monitoring the change in extracellular pH with a pH-sensitive
electrode as described previously [37,38]. The cells were used
at 3.5% or 7% haematocrit in lightly buffered saline medium
supplemented with 5 μM DIDS and 100 μM acetazolamide to
prevent bicarbonate/CO2-mediated proton movements [37,38].
The erythrocytes were pre-incubated for 1 h at room temperature
(22–25◦C) with or without AR-C155858 at the required
concentration prior to assaying lactate transport. This was
performed at 6◦C with substrate uptake initiated by addition of
10 mM L-lactate.Initialratesoftransportwerecalculatedbyﬁrst-
order regression analysis of the time course of pH change and
converted into nmol of H
+ per min by determining the pH change
induced by small additions of standardized NaOH.
Measurement of MCT transport activity in Xenopus oocytes
cRNA was prepared by in vitro transcription from the appropriate
linearized pGHJ plasmid (mMessage mMachine, Ambion)
and injected into X. laevis oocytes as described previously
[33]. For most assays 20 ng of cRNA was injected, but for
[
14C] kinetic assays, injection quantity was adjusted to ensure
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that uptake was linear with time. Further details can be
found in Supplementary Table S2 (at http://www.BiochemJ.org/
bj/425/bj4250523add.htm). Controls received the equivalent
volume (9.2 nl) of water. Oocytes were then cultured in OR3
medium for 72 h with fresh medium each day. Rates of L-lactate
transport by wild-type or chimaeric MCTs were determined
as described previously, either by following the change in
intracellularpHusingtheratiometricpH-sensitiveﬂuorescentdye
BCECF [2
 -7
 -bis(carboxyethyl)-5(6)-carboxyﬂuorescein] [6,38]
or by measuring uptake of [
14C] substrate (L-lactate or pyruvate)
[33]. For measurement of AR-C155858 sensitivity, ten oocytes
were placed in a six-well plate containing 5 ml of uptake buffer
[ 7 5m MN a C l ,2m MK C l ,0 . 8 2m MM g C l 2, 1 mM CaCl2 and
20 mM Mes (pH 6.0)] and allowed to pre-incubate for the
required time (usually 45 min) with or without AR-C155858
as required. Five oocytes were removed and placed into 50 μl
of uptake buffer containing L-[
14C]lactate (0.5 mM, 7.4 MBq/ml)
with or without AR-C155858 at the required concentration.
Incubation at room temperature was continued for the period
over which uptake was linear with time; this varied with the
construct employed, as detailed in Supplementary Table S2. The
oocytes were then rapidly washed ﬁve times with ice-cold uptake
buffer and, after the ﬁnal wash, each egg was transferred into
a scintillation vial and homogenized in 100 μlo f2 % (w/v)
SDS by vigorous vortex-mixing. Scintillation ﬂuid (10 ml of
Emulsiﬁer-Safe, PerkinElmer) was then added and [
14C] assayed
by scintillation counting.
For the determination of Km values for pyruvate and L-lactate,
oocytes were equilibrated in incubation buffer [75 mM NaCl,
2mMKCl,0.82mMMgCl 2,1 mMCaCl2 and20 mMTris/Hepes
(pH 7.4)] for 5 min and then four oocytes incubated with 40 μl
of uptake buffer containing [
14C]-labelled L-lactate or pyruvate
(7.4 MBq/ml) at a ﬁnal concentration of 0.2, 0.5, 1, 2, 5, 20,
50 and 75 mM. Incubation was continued for the period over
which uptake was linear with time (detailed in Supplementary
Table S2), following which oocytes were washed and prepared
for scintillation counting as above. Net MCT1-mediated uptake
of L-lactate was determined by subtracting the uptake by water-
injected oocytes determined at the same time.
MCT expression at the plasma membrane was conﬁrmed
by immunoﬂuorescence microscopy of oocytes sectioned by
embedding in chicken liver as described previously [33,39].
RESULTS
Determining the Ki of AR-C155858 for MCT1 in rat erythrocytes
Rat erythrocytes support very rapid lactate transport that is
mediated by three mechanisms. The majority is via MCT1, but
a small proportion may occur via the anion exchanger AE1
and by free diffusion of the undissociated lactic acid [26,40].
Transport mediated by AE1 can be blocked by 5 μM DIDS, a
concentration that has a minimal effect on MCT1 [37,38]. Using
a pH electrode to determine the extracellular increase in pH that
accompanies the proton-linked transport of 10 mM L-lactate into
erythrocytes at 6◦C we have investigated the inhibition of MCT1
by AR-C155858. It was ﬁrst established that inhibition by low
(nanomolar) concentrations of AR-C155858 reached equilibrium
within 30–45 min incubation at room temperature (results not
shown). Thus for detailed inhibitor titrations with increasing
concentrations of AR-C155858 we used 60 min incubation of
erythrocytes at both 3.5 and 7% haematocrit. After incubation
with inhibitor at room temperature, cell suspensions were
cooled to 6◦C before measurement of L-lactate transport and
determination of initial rates. In Figure 1 we show that the
Figure 2 MCT1 expressed in Xenopus oocytes is inhibited by AR-C155858
in a time- and concentration-dependent manner
Xenopus oocytes were injected with the appropriate cRNA and after 72h expression were
pre-incubated in pH6 oocyte transport buffer in the presence or absence of 0.1μMo r
1 μM AR-C155858 for the times shown. The uptake of 0.5 mM L-[14C]lactate uptake was
then determined after 2.5min over which period it was found to be linear with time. Data are
shownasmeans+ −S.E.Moftenseparateoocytes.Theinsetshowstheuptakeof20mM L-lactate
measuredatpH6.0usingthepH-sensitivedyeBCECF.Dataarepresentedforthesameoocytein
theabsenceofinhibitorandthenafter20minsuperfusionwith0.1 μMand1μMAR-C155858.
concentration-dependence of inhibition is almost linear up to
80% inhibition, as predicted for a very tight-binding inhibitor
whose concentration is less than the concentration of the target
protein (MCT1). By performing parallel experiments at two
cell densities (3.5% and 7% haematocrit) the data can be
ﬁtted by non-linear regression analysis to the equation for a
tight-binding non-competitive inhibitor using the total inhibitor
concentration and the haematocrit as the two x-variables [41,42].
This allowed us to determine values (+ −S.E. for the ﬁt shown)
for the Ki (2.3+ −1.4 nM), the number of binding sites (Et) for
AR-C155858 inhibition (1.29+ −0.09 nmol per ml of packed
cells) and the turnover number (kcat) of MCT1 in rat erythrocytes
(12.2+ −1.1 s
−1).
Time- and concentration-dependence of MCT inhibition by
AR-C155858 in Xenopus oocytes
In order to perform accurate comparisons of the afﬁnity of the
different MCT isoforms towards AR-C155858 we expressed
MCT1, MCT2 and MCT4 in X. laevis oocytes. It was ﬁrst
necessary to ensure that the time of incubation of oocytes with
inhibitor was sufﬁcient to allow compoundbinding to the MCT to
reach equilibrium. In Figure 2 the rate of [
14C]lactate uptake into
MCT1-expressing oocytes was determined after incubation with
0.1 μM AR-C155858 for 15, 30, 45 and 60 min. For each time
point,meandata(+ −S.E.M)fortenseparateoocytesarepresented.
The data show that, as with the erythrocytes, 45 min incubation
with inhibitor was sufﬁcient to give maximal inhibition. As
might be predicted, with 1 μM AR-C155858 inhibition occurred
much more quickly and was almost maximal at 5 min. This was
conﬁrmed by BCECF assay of transport as shown in the inset to
Figure 2. From these data we chose to use a 45 min incubation
time for comparing the relative potency of AR-C155858 as an
inhibitor of MCT1, MCT2 and MCT4. In Figure 3 we show that
the concentration-dependence of MCT1 follows a linear trend up
to 30 nM (70% inhibition) and then curves off towards 100%
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Figure 3 When expressed in Xenopus oocytes, MCT1 and MCT2, but not
MCT4, are sensitive to inhibition by AR-C155858
Xenopus oocytes were injected with appropriate cRNA or water and after 72h expression they
were incubated with the concentration of AR-C155858 shown for 45min prior to measurement
of L-[14C]lactateuptakeover2.5min.Dataareshownasthemeans+ −S.E.M.of15–40separate
oocytes for each inhibitor concentration. The inset images show the expression of the relevant
MCT in oocyte sections revealed using immunoﬂourescence microscopy with C-terminal
antibodies against the relevant MCT. Arrows indicate the location of the plasma membrane.
NotethatforMCT2asigniﬁcantproportionoftheMCTremainsinanintracellularcompartment.
inhibition at 100 nM. Again, this behaviour is that predicted for
a very high-afﬁnity inhibitor and thus consistent with the Ki for
AR-C155858 of 2.3 nM determined using rat erythrocytes. By
contrast, oocytes expressing MCT4 at levels supporting similar
rates of lactate transport revealed no signiﬁcant inhibition by
1 μM AR-C155858, and even at 10 μM AR-C155858 inhibition
was only approx. 20%. In oocytes expressing MCT2 the initial
rate of transport was less than for MCT1 and MCT4, consistent
with the poorer expression of MCT2 at the plasma membrane
as reported previously [38]. This is a consequence of MCT2
bindinglesswelltotheendogenousbasiginexpressedbyXenopus
oocytes than does MCT1 and MCT4 [38,43]. Nevertheless, it
is clear that MCT2 is potently inhibited by AR-C155858, and
the 70% inhibition seen at 10 nM is followed by a gradually
increasing inhibition which can only be explained by a Ki value
of signiﬁcantly less than 10 nM.
Extrapolation of the linear portion of the plot shown for MCT1
inhibition to zero carrier-mediated rate (i.e. water-injected rate)
provided an estimated concentration of MCT1 in the incubation
of 40 nM. Each egg was incubated in 10 μl so this represents
0.4 pmol of MCT1 per egg. The rate of L-lactate uptake was
approx. 95 pmol/egg per min which gives a turnover number
of 4 s
−1 for MCT1 in oocytes at 22◦C with 0.5 mM L-lactate.
Since the initial slope of the inhibitor plot for MCT2 cannot
be accurately determined, it is not possible to determine an
accurate turnover number for this isoform. Nevertheless, linear
extrapolation of the plot would give a maximal value for the
concentration of MCT2 to be approx. 15 nM, corresponding to a
maximal expression of MCT2 of 0.15 pmol per egg. This would
yield a minimum estimate of the turnover number for MCT2 in
oocytes at 22◦C with 0.5 mM L-lactate of 5 s
−1, which is similar
to MCT1.
AR-C155858 probably binds to MCT1 from the cytosolic side
The slow time-dependence of inhibition by AR-C155858 could
reﬂect slow binding to a site on the external surface or perhaps,
Figure 4 Microinjection of AR-C155858 inhibits MCT1 expressed in
Xenopus oocytes
MCT1 was expressed in Xenopus oocytes for 72h prior to inhibitor treatment and assay of
L-[14C]lactate uptake over 2.5min. For addition of AR-C155858 internally, 20 oocytes were
individually injected with 9.2 nl of 1mM AR-C155858 or DMSO as a control, incubated for
5 min in 5ml of pH6 transport buffer and washed once prior to transport assay. For incubation
with the equivalent amount of AR-C155858 added externally, 20 aliquots (9.2 nl) of 1mM
AR-C155858 were added to 5 ml of pH6 transport buffer (ﬁnal concentration of 35nM) and
incubatedwiththeoocytesfor5 minpriortoasinglewashandtransportassayasabove.Uptake
wascorrectedfortheuptakebywater-injectedeggsunderthesameconditionsandarepresented
as means+ −S.E.M. of 18–20 separate oocytes. The two images on the right-hand side show
the plasma membrane expression of MCT1 in control oocytes and those incubated for 1h with
1 μM AR-C155858 revealed by immunoﬂuorescence microscopy.
more likely, a slow permeation of the inhibitor into the cell
where it binds to an internal site on MCT1. In order to
discriminate between the two possibilities we microinjected
9.2 nl of 1 mM AR-C155858 into oocytes, corresponding to
a total internal concentration of approx. 23 μM (assuming an
internal volume of 0.4 μl per egg [44] and ignoring binding
to intracellular components). Each oocyte (20 in total) was
immediately transferred into 5 ml of pH 6 transport buffer and
then left for 5 min prior to washing once and determining the
rate of L-[
14C]lactate uptake. As a control, the same quantity of
inhibitor (184 nl corresponding to 20 oocytes worth of inhibitor)
was added to 5 ml of buffer (36.8 nM ﬁnal) prior to addition of 20
oocytes and 5 min incubation. These oocytes were subsequently
washed and transport determined as for AR-C155858-injected
oocytes. As an additional control, some oocytes were in-
jected with 9.2 nl of DMSO. The results in Figure 4 show that the
rate of L-lactate uptake was approx. 50% inhibited in the AR-
C155858-injectedoocytes,whereasthesamequantityofinhibitor
added outside was without effect. It might also be argued that
the slow time course of inhibition could reﬂect internalization
of MCT1. However, the immunoﬂuorescence results in Figure 4
conﬁrm that the expression of MCT1 at the plasma membrane
was unchanged in oocytes incubated with 1 μM AR-C155858 for
1 h to give full inhibition of transport.
AR-C155858 inhibition involves TM helices 7–10 in the C-terminal
half of MCT1
Since MCT1 is inhibited by AR-C155858, whereas MCT4 is not,
we made MCT1/4 chimaeras to establish the region on MCT1
to which the inhibitor binds. The structures of these MCT1/4
chimaerasareshownschematicallyin(A)ofeachrelevantFigure.
We ﬁrst created chimaeras in which the N-terminal half and large
intracellularloopwereofMCT1andtheC-terminalhalfwasfrom
MCT4. This chimaera (MCT1/4) was expressed at the plasma
membrane of oocytes and transported L-lactate, albeit at a greatly
reduced rate (Figure 5B). However, like MCT4, it was insensitive
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Figure 5 The binding site of MCT1 for AR-C155858 resides within the
C-terminal half of the transporter
(A)ShowsaschematicoftheMCT1/4andMCT4/1chimaerasused,withMCT1sequencebeing
shown in black and MCT4 sequence in grey. The numbered arrows indicate the position that
the switch was made between MCT1 and MCT4. Native and chimaeric MCTs were expressed
in oocytes for 72h prior to incubation with AR-C155858 after which assay of L-[14C]lactate
uptake was determined as described in Figures 2 and 3. Note that different times of uptake
were employed depending on the activity of the chimaera as detailed in Supplementary
Table S2 (at http://www.BiochemJ.org/bj/425/bj4250523add.htm). (B) Data on the absolute
rate of transport of each chimaera in the absence of inhibitor. (C) The activity at each inhibitor
concentration expressed as a percentage of the uninhibited rate, after the background uptake
rate of water-injected oocytes was subtracted. Data are shown as the means+ −S.E.M. of 20–50
separate oocytes for each condition. The inset images of (B) show the plasma membrane
expression of each native and chimaeric MCT revealed by immunoﬂuorescence microscopy.
to inhibition by AR-C155858 (Figure 5C). We also made the
reverse chimaera MCT4/1. It too was expressed at the plasma
membrane, although there appeared to be a signiﬁcant amount
of the chimaera that was in a vesicular compartment and not at
the plasma membrane (Figure 5B). Nevertheless, this MCT4/1
chimaera showed a sensitivity to AR-C155858 similar to MCT1
(Figure 5C). Thus our results imply that the binding site of
MCT1 for AR-C155858 is contained within the C-terminal half
of the molecule, beyond the intracellular loop between TMs 6
and 7.
Inordertodeﬁnethebindingsiteoftheinhibitormoreprecisely
we created additional chimaeras. We ﬁrst made chimaeras in
whicheithertheC-terminaltailofMCT1wasremovedorswapped
Figure6 TheC-terminusofMCT1 isnotinvolvedin AR-C155858sensitivity
(A)ShowsaschematicoftheMCT1/4andMCT4/1chimaerasused,withMCT1sequencebeing
shown in black and MCT4 sequence in grey. The numbered arrows indicate the position that
the switch was made between MCT1 and MCT4. Native and chimaeric MCTs were expressed
in oocytes for 72h prior to incubation with or without 0.1 μM AR-C155858 for 45min, after
whichassayof L-[14C]lactateuptakewasdeterminedover2.5minasdescribedinFigures2and
3. (B) Provides mean data (+ −S.E.M. for ten oocytes) on the absolute rate of transport of each
chimaeraintheabsenceandpresenceofinhibitor.Theinsetimagesshowtheplasmamembrane
expression of each native and chimaeric MCT revealed by immunoﬂuorescence microscopy.
forthatofMCT4asshownschematicallyinFigure6(A).Boththe
MCT1trncandMCT1/4cwereexpressedattheplasmamembrane
of oocytes, although a signiﬁcant amount of MCT1trnc remained
intracellular. Nevertheless, this chimaera still transported lactate
with rates similar to that seen with normal MCT1 and MCT4.
Although we did not perform detailed inhibitor titrations we
showed that both the MCT1/4c chimaera and MCT1trnc were
strongly inhibited by 0.1 μM AR-C155858, like MCT1 itself.
TheseresultsimplythatthebindingsiteforAR-C155858doesnot
require the C-terminal tail of MCT1. In order to establish which
of the C-terminal TM helices might be important for inhibitor
binding we compared the C-terminal TM sequences of MCT1,
MCT2 and MCT4 and found that it was within TM11 that MCT4
(inhibitor-insensitive) exhibited the greatest difference to MCT1
and MCT2 (inhibitor-sensitive). Thus we made chimaeras in
whichtheswitchbetweenMCT1andMCT4wasperformedatthe
startofTM11.Unfortunately,asshownintheinsettoFigure7(B),
the MCT1/4TM11 chimaera was not expressed properly at the
plasmamembraneandnoenhancementof L-lactatetransportover
water-injected eggs was detected. However, the MCT4/1TM11
chimaerawasexpressedattheplasmamembraneanddidtransport
L-lactate, albeit very slowly (Figure 7B). Subtraction of the
very low background rate of lactate transport by uninjected
oocytes, which was inhibited by AR-C155858, revealed that the
residual lactate transport activity mediated by MCT4/1TM11 was
insensitive to inhibition by AR-C155858. This suggests that the
binding site for AR-C155858 does not involve TMs 11 and 12 as
we had initially reasoned and must therefore involve TMs 7–10.
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.528 M. J. Ovens and others
Figure 7 A region within TMs 7–10 of MCT1 is required for sensitivity to
AR-C155858
(A)ShowsaschematicoftheMCT1/4andMCT4/1chimaerasused,withMCT1sequencebeing
shown in black and MCT4 sequence in grey. The numbered arrows indicate the position that
the switch was made between MCT1 and MCT4. Native and chimaeric MCTs were expressed
in oocytes for 72h prior to incubation with or without 0.1 μM AR-C155858 for 45min, after
which assay of L-[14C]lactate uptake was determined over 1h. This prolonged uptake period
was required because of the low rates of transport being measured. (B) Provides mean data
(+ −S.E.M. for ten oocytes) on the absolute rate of transport of each chimaera in the absence and
presence of inhibitor. The inset images show the plasma membrane expression of each native
and chimaeric MCT revealed by immunoﬂuorescence microscopy.
Kinetic properties of the MCT1/4 and MCT4/1 chimaeras
The relatively low rates of transport seen with the MCT4/1 and
MCT1/4 chimaeras may reﬂect a high Km for L-lactate and thus
lowratesoftransportwhenmeasuredat0.5 mM L-lactate.Inorder
to investigate this possibility, and to provide some clues as to how
thetwohalvesoftheMCTmightbeinvolvedinsubstratebinding,
the Km values of the chimaeras for L-lactate and pyruvate were
determined(Table1).TheMCT4/1chimaeraexhibitedaKm value
for L-lactate of 15–25 mM, depending on whether the BCECF or
radioactive assay was used, whereas both techniques gave a Km
value for pyruvate of 8–9 mM. These Km values are similar to that
ofMCT4inthecaseof L-lactate,butintermediatebetweenMCT1
and MCT4 for pyruvate. In the case of the MCT4/1 chimaera, Km
values were too high to be determined radioactively, but using
BCECF they were found to be 209+ −72 mM for L-lactate and
27+ −5 mM for pyruvate. Thus with this chimaera also, the Km for
pyruvate was intermediate between MCT1 and MCT4, whereas
the Km for L-lactate was much higher than that for either isoform.
DISCUSSION
Previously,anewclassofspeciﬁcandextremelypotentinhibitors
ofMCT1havebeendiscoveredbyAstraZenecathatwerereported
to show no binding to MCT4 and exhibit lower-afﬁnity bind-
ing to MCT2 [30–32]. The Kd values for these inhibitors binding
to endogenous MCT1 in rat and human cells was found to be in
the low nanomolar region or less, as was also found for MCT1
expressed in Ins-1 cells that contain little or no endogenous
MCT1 [30,31]. Similar Kd values were determined for MCT1
expressed in yeast [30], and the Ki value of AR-C155858 for
MCT1 we have determined in rat erythrocytes of 2.3+ −1.4 nM
is entirely consistent with the Ki of 1.2 nM for binding of AR-
C155858 to human erythrocyte MCT1 derived from radioligand-
binding experiments [45].
The turnover number for MCT1 can be calculated using AR-C155858
The inhibitor titration in rat erythrocytes has allowed us to
determine the concentration of MCT1 in these cells to be
1.29+ −0.09 nmol per ml of packed cells. Since the number of
erythrocytes in 1 ml of packed blood is known to be approx.
10
10 [26] it is possible to calculate that there are approx. 80000
molecules of MCT1 per rat erythrocyte. This value is quite
similar to the value of 46000+ −11000 determined previously
by [
3H] inhibitor binding [30] and represents approx. 8% of
the value for the anion exchanger AE1 [26]. Using the rate of
L-lactate transport and the concentration of MCT1 we calculated
the turnover number (kcat) to be 12.2+ −1.1 s
−1 at 6◦C. Since
we have previously determined the temperature-dependence of
MCT1 [29], we are able to calculate that the rate of L-lactate
transport by rat erythrocytes at room temperature will be approx.
7-foldhigherthanat6◦C.Thiswouldbringthepredictedturnover
number for MCT1 in rat erythrocytes to approx. 85 s
−1 which
is similar to the value of 35 s
−1 determined for the glucose
transporter GLUT1 in rat erythrocytes at 20◦C [46,47], but
approx. 5-fold less than the kcat determined for endogenous
Table 1 Km values of MCT chimaeras for L-lactate and pyruvate
The Km values reported were derived using either L-[14C]lactate uptake or by monitoring changes in intracellular pH with BCECF as described in the Experimental section. Data are given + −S.E.M.
derived from the ﬁt of the mean data to the Michaelis–Menten equation by non-linear least squares analysis. The n values given represent the number of separate eggs used for each substrate
concentration. No L-[14C]lactate uptake data are provided for the MCT4/1 chimaera because the very high Km values required the use of high substrate concentrations for which the speciﬁc activity
became too low to measure uptake of L-[14C]lactate accurately.
Km value (mM) using [14C] substrate Km value (mM) using BCECF
MCT form Lactate Pyruvate Lactate Pyruvate
MCT1 5.7+ −1.2 (n=16) 1.2+ −0.2 (n=16) 3.5* 1*
MCT4 12.9+ −2( n=16) 103+ −28 (n=24) 28* 150*
MCT1/4 26.5+ −5.7 (n=16) 8.9+ −2( n=16) 15.8+ −2.6 (n=7) 8.5+ −1.9 (n=9)
MCT4/1 – – 209.2+ −71.9 (n=7) 27.3+ −5.2 (n=8)
*BCECF data for MCT1 and MCT4 are taken from [6].
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.AR-C155858 inhibition of MCTs 529
humanGLUT1inerythrocytesorwhenoverexpressedinXenopus
oocytes [48].
When expressed in Xenopus oocytes, MCT1 also showed
time-dependent inhibition by AR-C155858 (Figure 2) with the
extent of inhibition being linear with respect to AR-C155858
concentrations up to approx. 70% inhibition (Figure 3). This
is consistent with a very low (nanomolar) Ki value determined
in erythrocytes. By extrapolation of the linear portion of the
inhibitor titration we were able to estimate that the amount of
MCT1 expressed at the plasma membrane was approx. 0.4 pmol
per oocyte. From this value and the rate of lactate transport, the
turnover number of MCT1 in oocytes at 22◦C was calculated
to be 4 s
−1. However, this value was determined at 0.5 mM
L-lactate and thus cannot be compared directly with the value
of 85 s
−1 calculated for rat erythrocytes at 22◦C with 10 mM
L-lactate.TheKm forMCT1inerythrocytesandoocytesisapprox.
3.5 mM [6,29], and thus from Michaelis–Menten kinetics the rate
of transport at 10 mM L-lactate would be predicted to be 6-fold
higher than at 0.5 mM. This would increase the turnover number
of MCT1 in oocytes to 24 s
−1, which is approx. 30% of the value
determined for MCT1 in erythrocytes. However, we have shown
previously that the rate of L-lactate uptake by oocytes determined
radioactively underestimates the true transport rate deter-
mined with BCECF [6]. This is because of an unstirred layer
effect that slows diffusion of L-[
14C]lactate taken up into the body
oftheoocyte.Thusoverallthereisreasonableagreementbetween
the values measured in erythrocytes and oocytes.
AR-C155858 is a potent inhibitor of MCT1 and MCT2, but not MCT4
In agreement with competition-binding studies of MCTs
expressed in yeast for related compounds [30], we have shown
that AR-C155858 inhibits both MCT1 and MCT2, but not MCT4
when expressed in oocytes (Figure 3). Although we were unable
to determine an accurate Ki value for inhibition of MCT2 by AR-
C155858,wecanconcludefromtheshapeoftheinhibitortitration
that the value must be signiﬁcantly less than 10 nM. In previous
studies of inhibitor binding to MCT1 and MCT2 expressed in
yeast, Kd values of 4.9 and 100 nM respectively were determined
(P. A. Rugman, A. P. Jackson and C. M. Murray, unpublished
work). For MCT1 this represents a reasonable agreement with the
Ki values for endogenous MCT1 in rat and human cells derived
in the present study and previously [44]. However, this is not
the case for MCT2 where the yeast binding data suggest that
the afﬁnity of MCT2 for AR-C155858 is more than an order of
magnitudelessthanforMCT1.Oneexplanationforthisdifference
may be the absence of either basigin or embigin when MCTs
are expressed in yeast, and this might affect inhibitor binding.
In this context it may be noted that inhibition of MCT1 and
MCT2 by the organomercurial reagent p-chloromercuribenzene
sulfonate also depends on the associated ancillary protein [38].
Our results would also imply that interpretation of metabolic
studies in which AR-C122982 has been used to discriminate
between MCT1- and MCT2-mediated lactate transport [49] may
not be straightforward.
The binding site for AR-C155858 involves TMs 7–10 of MCT1, and
probably faces the cytosol
The use of MCT1/MCT4 chimaeric transporters reveals that the
binding site for AR-C155858 is contained within the C-terminal
half of the transporter. Thus MCT1/4, like MCT4, was insensitive
to inhibition by AR-C155858, whereas MCT4/1 was inhibitor-
sensitive, like MCT1 (Figure 5). The C-terminal tail of MCT1
appears to have no major effect on the sensitivity to inhibition
by AR-C155858 since potent inhibition by AR-C155858 was
still observed when it was either removed or replaced with the
tail of MCT4 (Figure 6). However, the chimaera containing TMs
1–10 of MCT4 and TMs 11 and 12 plus the C-terminal tail of
MCT1 was insensitive to AR-C155858 (Figure 7). These results
demonstrate that the binding site for AR-C155858 is contained,
at least in part, within TMs 7–10 of MCT1. The slow time-
dependence of inhibition by AR-C155858 (Figure 2) could be
explained either by the inhibitor having to enter the cell before
binding to an intracellular site on MCT1 or by internalization
of MCT1 upon inhibitor binding. However, we showed that
no MCT1 internalization occurred, even at full inhibition, and
that the inhibitor worked well if microinjected into oocytes
(Figure 4). These results imply that the binding site for AR-
C15585 probably faces the cytosol, where our molecular model
of MCT1 predicts TMs 7 and 10 to form part of the inward
facing substrate-binding pocket [33,36]. This is also consistent
with earlier observations that Phe
360 in TM10 is involved in
substrate binding since its mutation to cysteine allows MCT1
to accommodate the larger monocarboxylate mevalonate [7,50].
Furthermore, we have previously shown that Asp
302 and Arg
306 in
TM8 are critical residues in the translocation cycle. However,
analysis of the kinetics of MCT1/4 and MCT4/1 chimaeras
suggest that substrate binding may not be exclusively located
within the C-terminal half of MCT1. Thus both the C- and
N-terminal halves of the MCT inﬂuence the kinetics of transport
(Table 1). This is entirely consistent with our recent molecular
model of MCT1 which predicts that the substrate-binding pocket
and translocation channel involve helices from both the C- and
N-terminal domains with critical roles for Lys
38 in TM1, and
Asp
302 plus Arg
306 in TM8 [33,36].
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AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1
and MCT2 that binds to an intracellular site involving transmembrane
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Table S1 Primers used in PCR generation of chimaeric MCTs
MCT form MCT fragment Left-hand primer Right-hand primer
MCT1/4 MCT1 (TM1–6) TCTTGGAATTCATCGACACCT GGACAAGTCCAGGAATTTATTAAC
MCT4 (TM7–12) CTGGACTTGTCCGTCTTCCGAGAC GGACCTCTTCCCTGCTCCCTGC
MCT4/1 MCT4 (TM1–6) CCAAGGTGAAACCAGCCCTCCTGG GGACAAGTCCAGCAGGCGCGG
MCT1 (TM7–12) CTGGACTTGTCCCTGTTTAC ACACAAATGTCCACTGTCT
MCT1/4TM11 MCT1 (N-terminus to TM10) TCTTGGAATTCATCGACACCT CCCACAGCACTGGAGAAC
MCT4 (TM11/12 and C-terminus) CCCAGAGGTTCTCCAGTGC GGACCTCTTCCCTGCTCCCTGC
MCT4/1TM11 MCT4 (N-terminus to TM10) CCAAGGTGAAACCAGCCCTCCTGG CCCACAGCACTGGAGAAC
MCT1 (TM11/12 and C-terminus) CCCAGAGGTTCTCCAGTGC ACACAAATGTCCACTGTCT
MCT1trnc MCT1 (N-terminus to TM12 end) TCTTGGAATTCATCGACACCT AAGTCGATAATTGATGCCC
MCT1/4c MCT1 (TMs) TCTTGGAATTCATCGACACCT GCAGCACAAGGGAAGAGGTAGAGGCCT
MCT4 (C-terminus) AGGCCTCTACCTCTTCCCTTGTGCTGC GGACCTCTTCCCTGCTCCCTGC
Site-directed mutagenesis GGCCTCTACCTCTTCCTTGTGCTGCTGCTG (sense strand primer) CAGCAGCAGCACAAGGAAGAGGTAGAGGCC (antisense strand primer)
MCT4/1c MCT4 (TMs) CCAAGGTGAAACCAGCCCTCCTGG CCCATACCAATGAGGAGGTGAGCACCT
MCT1 (C-terminus) AGGTGCTCACCTCCTCATTGGTATGGG ACACAAATGTCCACTGTCT
Site-directed mutagenesis CCTCCTCATTGGTATTGGGCATCAATTATCG (sense strand primer) CGATAATTGATGCCCAATACCAATGAGGAGG (antisense strand primer)
Table S2 cRNA injection quantities and [14C]-substrate uptake times used for Xenopus oocyte transport studies
N/A, not applicable.
AR-C155858 studies Kinetic studies
MCT form cRNA injected (ng) [14C]-substrate uptake time for assay (min) cRNA injected (ng) [14C]-substrate uptake time for assay (min)
MCT1 20 2.5 5 (for L-lactate) 5
2 (for pyruvate) 5
MCT4 20 2.5 5 (for L-lactate) 5
20 (for pyruvate) 10 (for 0.2, 0.5, 1, 2 and 5 mM)
2.5 (for 20, 50 and 75mM)
MCT1/4 20 20 20 (for L-lactate) 20 (for 0.2, 0.5, 1, 2 and 5 mM)
5( f o r2 0 ,5 0a n d7 5m M )
10 (for pyruvate) 5 (for 0.2, 0.5, 1, 2 and 5 mM)
10 (for 20, 50 and 75 mM)
MCT4/1 20 20 N/A N/A
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